Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Auron Therapeutics Inc.

News headline image
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Therapeutics Announces Poster Presentation at 2025 AACR Annual Meeting
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Therapeutics Expands Leadership with Appointment of Glenn Goddard as Chief Financial Officer
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Presents New Preclinical Data for AUTX-703 in AML at ASH Annual Meeting
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron to Present AUTX-703 Preclinical Data 2024 ENA Symposium
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Presents Preclinical Data at American Chemical Society Annual Meeting
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Announces Oral Presentation on Preclinical Data from Proprietary AURIGIN™ Platform at the AI in Biomedicine Keystone Symposia
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Announces Poster Presentations at 2024 AACR Annual Meeting
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA
From Auron Therapeutics Inc.
Via GlobeNewswire
News headline image
Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer
From Auron Therapeutics Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.